Zhihua Kou

Dr. Zhihua Kou


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2015 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
YYYi Yang
Yi Yang
WSWeilai Sun
Weilai Sun
JGJingjing Guo
Jingjing Guo
GZGuangyu Zhao
Guangyu Zhao
SSShihui Sun
Shihui Sun
YZYusen Zhou
Yusen Zhou
The development of an HIV-1 vaccine that is capable of inducing effective and broadly cross-reactive humoral and cellular immune responses remains a challenging task because of the extensive diversity of HIV-1, the difference of virus subtypes (clades) in different geographical regions, and the polymorphism of human leukocyte antigens (HLA). We performed an in silico design of 3 DNA vaccines, designated pJW4303-MEG1, pJW4303-MEG2 and pJW4303-MEG3, encoding multi-epitopes that are highly conserved within the HIV-1 subtypes most prevalent in China and can be recognized through HLA alleles dominant in China. The pJW4303-MEG1-encoded protein consisted of one Th epitope in Env, and one, 2, and 6 epitopes in Pol, Env, and Gag proteins, respectively, with a GGGS linker sequence between epitopes. The pJW4303-MEG2-encoded protein contained similar epitopes in a different order, but with the same linker as pJW4303-MEG1. The pJW4303-MEG3-encoded protein contained the same epitopes in the same order as that of pJW4303-MEG2, but with a different linker sequence (AAY). To evaluate immunogenicity, mice were immunized intramuscularly with these DNA vaccines. Both pJW4303-MEG1 and pJW4303-MEG2 vaccines induced equally potent humoral and cellular immune responses in the vaccinated mice, while pJW4303-MEG3 did not induce immune responses. These results indicate that both epitope and linker sequences are important in designing effective epitope-based vaccines against HIV-1 and other viruses.

1 March 2020 in Molecular Therapy Nucleic Acids
Verified
Journal Article
Open access
HLHao Li
Hao Li
SWShan Wang
Shan Wang
XDXue Dong
Xue Dong
QLQiao Li
Qiao Li
MLMin Li
Min Li
ZKZhihua Kou
Zhihua Kou
The CRISPR-Cas9 system has been applied to DNA editing with precision in eukaryotic and prokaryotic systems, but it is unable to edit RNA directly. A recently developed CRISPR-Cas13a system has been shown to be capable of effectively knocking down RNA expression in mammalian and plant cells. In this study, we employ the CRISPR-Cas13a system to achieve reprogrammable inactivation of dengue virus in mammalian cells. Quantitative reverse transcription PCR (qRT-PCR), fluorescence-activated cell sorting (FACS), and plaque assays showed that CRISPR RNA (crRNA) targeting the NS3 region led to the greatest viral inhibition among 10 crRNAs targeting different regions along the dengue viral genomic RNA. Deletions and insertions had also been found adjacent to the NS3 region after NS3-crRNA/Cas13a complex transfection. Our results demonstrate that the CRISPR-Cas13a system is a novel and effective technology to inhibit dengue viral replication, suggesting that such a programmable method may be further developed into a novel therapeutic strategy for dengue and other RNA viruses.

1 April 2015 in Vaccine
Verified
Journal Article
Closed access
JGJingjing Guo
Jingjing Guo
YYYi Yang
Yi Yang
WXWenjun Xiao
Wenjun Xiao
WSWeilai Sun
Weilai Sun
HYHong Yu
Hong Yu
YZYusen Zhou
Yusen Zhou

1 January 2020 in Vaccine
Verified
Journal Article
Closed access
WSWeilai Sun
Weilai Sun
QLQiao Li
Qiao Li
XNXiuzhe Ning
Xiuzhe Ning
YYYi Yang
Yi Yang
JGJingjing Guo
Jingjing Guo
ZKZhihua Kou
Zhihua Kou

10 March 2017 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
YYYi Yang
Yi Yang
QZQing Zhu
Qing Zhu
WSWeilai Sun
Weilai Sun
JGJingjing Guo
Jingjing Guo
XNXiuzhe Ning
Xiuzhe Ning
YZYusen Zhou
Yusen Zhou
The effective protective HIV vaccine should elicit either protective antibodies or effective T cell response, or both. To improve the efficacy of HIV-1 vaccines, HLA polymorphism and HIV-1 diversity are 2 key factors to be considered for vaccine development. In this study, we expressed a recombinant multi-epitope protein MEP1 which has the same amino acid sequence as a DNA vaccine for Chinese population in our previous report. We found that MEP1 alone could elicit moderate levels of humoral and cellular immune responses, but these responses could not provide protection from challenge with a recombinant virus rTTV-lucgag, which expresses Gag of HIV-1 CRF_07BC. Nevertheless, when MEP1 was immunized with aluminum adjuvant, both humoral and cellular immune responses were significantly increased, and they were protective against virus infection; meanwhile, MEP1 with aluminum not only elicited early (10 d post immunization) but also a long-term (at least 44 weeks post immunization) immune responses in BALB/c mice. These results suggested that MEP1 has the potential to be developed as an effective vaccine candidate, and that suitable adjuvant is necessary for this protein to generate protective immune responses.